Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28444234 | 0.90 | — | — | |
| SCHEMBL3185516 | 0.73 | CTSV (0.40) | MEN1ALDH1A1KMT2A | |
| SCHEMBL14646344 | 0.70 | MAPK1 (0.36) | MEN1ALDH1A1KMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL3172425 | 0.70 | KDM4E (0.31) | — | |
| SCHEMBL3194979 | 0.68 | KDM4E (0.38) | — | |
| SCHEMBL8969180 | 0.68 | RAB9A (0.40) | MEN1ALDH1A1KMT2A | |
| SCHEMBL24519282 | 0.67 | TSHR (0.47) | ALDH1A1APOBEC3AAPOBEC3GEPHX1 | |
| SCHEMBL8969288 | 0.67 | RAB9A (0.39) | MEN1ALDH1A1KMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL8969116 | 0.67 | RAB9A (0.39) | MEN1ALDH1A1KMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL13879136 | 0.67 | CTSK (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | claimed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | claimed |
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | TYR, MC1R, PDE7A | MEN1 4223/4885ALDH1A1 2889/4885KMT2A 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.